Wells Fargo’s Lexeo Therapeutics LXEO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$46.6K Sell
13,783
-45,582
-77% -$206K ﹤0.01% 5544
2026
Q2
$276K Buy
59,365
+34,372
+138% +$186K ﹤0.01% 4992
2026
Q1
$143K Sell
24,993
-45,743
-65% -$324K ﹤0.01% 4906
2025
Q4
$702K Buy
70,736
+51,474
+267% +$470K ﹤0.01% 4218
2025
Q3
$128K Buy
19,262
+3,937
+26% +$19K ﹤0.01% 5182
2025
Q2
$61.6K Buy
15,325
+3,916
+34% +$12.9K ﹤0.01% 5434
2025
Q1
$39.6K Buy
11,409
+253
+2% +$1.12K ﹤0.01% 5474
2024
Q4
$73.4K Buy
11,156
+3,714
+50% +$29.3K ﹤0.01% 5352
2024
Q3
$67.3K Buy
7,442
+4,101
+123% +$48.9K ﹤0.01% 5231
2024
Q2
$53.6K Sell
3,341
-28
-0.8% -$407 ﹤0.01% 5268
2024
Q1
$52.8K Buy
3,369
+3,297
+4,579% +$51.6K ﹤0.01% 5236
2023
Q4
$966 Buy
+72
New +$894 ﹤0.01% 6232

Other funds holding LXEO

Wells Fargo's LXEO Position: Q3 2026 in Review

Wells Fargo reduced its Lexeo Therapeutics (LXEO) stake by 77% in Q3 2026, selling an estimated $206K and leaving 13,783 shares worth $46.6K. The position accounts for ﹤0.01% of the portfolio, ranked #5544.

Wells Fargo first reported a position in LXEO in Q4 2023 and has held it in 12 quarters since. The position peaked at $702K in Q4 2025. 153 funds tracked by Wall St. Rank hold LXEO as of Q3 2026.

  • Wells Fargo held 13,783 shares of Lexeo Therapeutics worth $46.6K as of Q3 2026.
  • Wells Fargo sold 45,582 Lexeo Therapeutics shares in Q3 2026, an estimated $206K.
  • Lexeo Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q3 2026, its #5544 holding.
  • Wells Fargo first reported a position in Lexeo Therapeutics in Q4 2023 and has held it in 12 quarters since.
  • Wells Fargo's Lexeo Therapeutics position peaked at $702K in Q4 2025.
  • 153 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q3 2026.

Based on Wells Fargo's 13F filing for Q3 2026, filed 16 Nov 2026.